{"id":123849,"date":"2026-02-26T06:51:08","date_gmt":"2026-02-26T06:51:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-pa\/123849\/"},"modified":"2026-02-26T06:51:08","modified_gmt":"2026-02-26T06:51:08","slug":"orasure-closes-the-book-on-transition-year-of-2025-bethelehm-area","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-pa\/123849\/","title":{"rendered":"OraSure closes the book on &#8216;transition year&#8217; of 2025 | Bethelehm Area"},"content":{"rendered":"<p>BETHLEHEM, Pa.- 2025 is officially in the rearview mirror for OraSure Technologies (OTI).\u00a0<\/p>\n<p>That might be a good thing, given the company&#8217;s continued struggle to find its footing in a post-COVID-19 world.<\/p>\n<p>The medical technology company, which makes\u00a0diagnostic tests and sample collection devices used in healthcare, has unveiled its fiscal fourth quarter (Q4) and full-year results for 2025.<\/p>\n<p>President and CEO\u00a0Carrie Eglinton Manner has previously referred to 2025 as a transition year, and did so again Wednesday evening, during a webcast discussion of the company&#8217;s balance sheet.<\/p>\n<p>But, she said, &#8220;here in 2026 we are already seeing signs of market stabilization, and we are also well positioned to capitalize on the growth opportunities that our near-term product roadmap can unlock.&#8221;<\/p>\n<p>Late last year, OraSure submitted applications to the Food and Drug Administration (FDA) for clearance for a pair of products: a rapid molecular self-test for the types of bacteria that cause the sexually transmitted infections (STIs) Chlamydia and gonorrhoeae; and for\u00a0an at-home urine collection device for various STIs.<\/p>\n<p>Also, the company has been authorized to distribute its\u00a0OraQuick HIV Self-Test in Canada.<\/p>\n<p>The numbers<\/p>\n<p>OraSure reported that total net revenue for the fourth quarter of 2025 decreased 29% to $26.8 million, down from $37.4 million in the fourth quarter of 2024.\u00a0Core revenue, which excludes COVID-19, molecular services, and risk assessment testing revenue, was right behind at $26.7 million.<\/p>\n<p>The company has shed the risk assessment and molecular services components of its business.<\/p>\n<p>Core revenue for the year was recorded as $115 million, down 38% from 2024. Last year, COVID-19 diagnostics only contributed $624,000 to OTI&#8217;s bottom line. In 2024, that figure was $45.1 million.<\/p>\n<p>Also, GAAP (Generally Accepted Accounting Principles) operating loss in the fourth quarter was $20.1 million compared to an operating loss of $12.4 million in the fourth quarter of 2024.<\/p>\n<p>Non-GAAP operating loss was $15.2 million in the fourth quarter compared to non-GAAP operating loss of $6.7 million in the fourth quarter of 2024.<\/p>\n<p>Diluted earnings per share was -$0.27 for Q4, and -$0.94 for the full year.<\/p>\n<p>For the first quarter of 2026, OraSure is guiding to revenue of $26 million to $29 million.\u00a0<\/p>\n<p>In the markets\u00a0<\/p>\n<p>Shares of OraSure (NASDAQ: OSUR) were listed at $2.80 when markets closed on Wednesday. That&#8217;s near the middle of their 52-week range. The company has a market capitalization of $202.3 million.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"BETHLEHEM, Pa.- 2025 is officially in the rearview mirror for OraSure Technologies (OTI).\u00a0 That might be a good&hellip;\n","protected":false},"author":2,"featured_media":107123,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[119,121,120,51547,58127,9090,58126,58128,58130,51543,58129,58125],"class_list":["post-123849","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allentown","tag-allentown","tag-allentown-headlines","tag-allentown-news","tag-diagnostic-tests","tag-fda-clearance","tag-financial-results","tag-hiv-self-test","tag-market-stabilization","tag-operating-loss","tag-orasure-technologies","tag-post-covid-19","tag-sti-testing"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/123849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/comments?post=123849"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/123849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media\/107123"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media?parent=123849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/categories?post=123849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/tags?post=123849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}